Stockscreener 앱 받기
4.27
10.15%
0.33
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 - The Manila Times
Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire
Protara's Bladder Cancer Drug TARA-002 Phase 2 Trial: 12-Month Efficacy Data Reveal Coming at Major Conference - Stock Titan
Examining TARA’s book value per share for the latest quarter - uspostnews.com
Brokerages Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $22.50 - Defense World
Protara Therapeutics (NASDAQ:TARA) Earns Sector Outperform Rating from Analysts at Scotiabank - Defense World
Protara Therapeutics Announces Appointment of Leonardo Viana Nic - GuruFocus
Scotiabank Initiates Coverage of Protara Therapeutics (TARA) with Sector Outperform Recommendation - Nasdaq
Scotiabank Initiates Protara Therapeutics at Sector Outperform With $12 Price Target - marketscreener.com
Protara Therapeutics (TARA) Rated Outperform with $12 Target by Scotiabank | TARA Stock News - GuruFocus
Protara Therapeutics (TARA) Names Leonardo Viana Nicacio as New Chief Medical Officer | TARA Stock News - GuruFocus
Protara Therapeutics Names Leonardo Viana Nicacio CMO - MarketScreener
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer - The Manila Times
Strategic Leadership Boost: Protara Gains 20-Year Oncology Expert as CMO Ahead of Key Trial Data - Stock Titan
Could Protara's ADVANCED-2 Trial Data Trigger A Stock Rally? - RTTNews
Protara Therapeutics to Present Interim Analysis from the Phase - GuruFocus
Commonwealth Equity Services LLC Has $195,000 Stock Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara to present bladder cancer trial data at AUA meeting By Investing.com - Investing.com Canada
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade - MSN
Protara to present bladder cancer trial data at AUA meeting - Investing.com Australia
Protara Therapeutics to Present Interim Analysis from the - GlobeNewswire
Critical Phase 2 Data Coming: TARA-002 Shows Promise in Treating Resistant Bladder Cancer - Stock Titan
Cantor Fitzgerald Initiates Coverage of Protara Therapeutics (TARA) with Overweight Recommendation - MSN
Protara Therapeutics officer sells shares worth $96,144 By Investing.com - Investing.com Australia
Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results (TARA) - Seeking Alpha
Protara Therapeutics officer sells shares worth $96,144 - Investing.com India
Cantor Fitzgerald Brokers Lower Earnings Estimates for TARA - Defense World
Cantor Fitzgerald Predicts TARA FY2025 Earnings - Defense World
Protara Therapeutics (NASDAQ:TARA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Contrast - Defense World
Protara reveals choline deficiency in parenteral support patients By Investing.com - Investing.com South Africa
Protara reveals choline deficiency in parenteral support patients - Investing.com
Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - GlobeNewswire
Protara Therapeutics (NASDAQ:TARA) Research Coverage Started at Cantor Fitzgerald - Defense World
Cantor Fitzgerald sets Overweight rating on Protara stock - Investing.com India
Cantor Fitzgerald Initiates Coverage on Protara Therapeutics With Overweight Rating -March 14, 2025 at 07:33 am EDT - Marketscreener.com
Analysts Set Expectations for TARA Q1 Earnings - Defense World
Protara Therapeutics (NASDAQ:TARA) Coverage Initiated by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Protara Therapeutics (TARA) with Outperform Recommendation - Nasdaq
HC Wainwright Issues Positive Forecast for TARA Earnings - Defense World
What is HC Wainwright’s Forecast for TARA FY2029 Earnings? - Defense World
Protara Therapeutics’ (TARA) Buy Rating Reiterated at HC Wainwright - Defense World
Protara Therapeutics’ TARA-002 Shows Promising Efficacy and Safety in HR-NMIBC, Earning Buy Rating - TipRanks
H.C. Wainwright maintains Buy rating on Protara stock, $23 target By Investing.com - Investing.com UK
Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Protara Therapeutics: Q4 Earnings Snapshot - Midland Daily News
Protara Therapeutics Reports Progress and Financial Results - TipRanks
0.39%
0.80%
자본화:
|
볼륨(24시간):